| __timestamp | Opthea Limited | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2652041 | 72471000 |
| Thursday, January 1, 2015 | 2361587 | 89204000 |
| Friday, January 1, 2016 | 4472869 | 106010000 |
| Sunday, January 1, 2017 | 5030957 | 137905000 |
| Monday, January 1, 2018 | 4988941 | 159888000 |
| Tuesday, January 1, 2019 | 5196412 | 158425000 |
| Wednesday, January 1, 2020 | 6652774 | 200677000 |
| Friday, January 1, 2021 | 18418247 | 304759000 |
| Saturday, January 1, 2022 | 24827066 | 377221000 |
| Sunday, January 1, 2023 | 41896408 | 336361000 |
| Monday, January 1, 2024 | 15488619 |
Cracking the code
In the competitive landscape of pharmaceuticals, understanding spending patterns is crucial. Opthea Limited and Supernus Pharmaceuticals, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Opthea's SG&A expenses surged by over 1,400%, peaking in 2023. In contrast, Supernus Pharmaceuticals experienced a more stable growth, with a 360% increase, reaching its highest in 2022. This divergence highlights Opthea's aggressive expansion strategy, while Supernus maintains a steady growth trajectory. Notably, 2024 data for Supernus is missing, indicating potential reporting delays or strategic shifts. These insights provide a window into each company's operational focus and market positioning, offering valuable information for investors and industry analysts alike.
SG&A Efficiency Analysis: Comparing AbbVie Inc. and Opthea Limited
Regeneron Pharmaceuticals, Inc. or Opthea Limited: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of argenx SE and Opthea Limited
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc.
BeiGene, Ltd. or Opthea Limited: Who Manages SG&A Costs Better?
Genmab A/S and Supernus Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Incyte Corporation vs Opthea Limited: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of BioMarin Pharmaceutical Inc. and Supernus Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Opthea Limited and Protagonist Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Axsome Therapeutics, Inc. or Supernus Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Perrigo Company plc and Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? MorphoSys AG or Supernus Pharmaceuticals, Inc.